Protecting the brain from nerve agent exposure
Antiglutamatergic Therapy to Protect the Brain Against Nerve Agents
['FUNDING_U01'] · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · NIH-10908291
This study is testing a new drug called LY293558 to see if it can help protect the brain and control seizures caused by nerve agents, with the hope of improving treatment options for people who experience serious brain injuries from these toxic exposures.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HENRY M. JACKSON FDN FOR THE ADV MIL/MED (nih funded) |
| Locations | 1 site (BETHESDA, UNITED STATES) |
| Trial ID | NIH-10908291 on ClinicalTrials.gov |
What this research studies
This research focuses on developing effective treatments to protect the brain from the harmful effects of nerve agents, which can cause severe seizures and brain damage. The approach involves testing a specific drug, LY293558, which has shown promising results in animal models by providing better seizure control and neuroprotection compared to current treatments. The goal is to create a medical countermeasure that can be used in emergencies involving nerve agent exposure, ultimately saving lives and reducing long-term health issues. Patients may benefit from advancements in treatment options for acute brain injuries caused by such toxic exposures.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults over 21 years old who may be at risk of exposure to nerve agents, such as military personnel or first responders.
Not a fit: Patients who are not at risk of nerve agent exposure or those with pre-existing severe neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that prevent brain damage and improve survival rates after nerve agent exposure.
How similar studies have performed: Previous research has shown that similar approaches using AMPA/GluK1 receptor antagonists have been effective in animal models, indicating potential for success in human applications.
Where this research is happening
BETHESDA, UNITED STATES
- HENRY M. JACKSON FDN FOR THE ADV MIL/MED — BETHESDA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRAGA, MARIA F. — HENRY M. JACKSON FDN FOR THE ADV MIL/MED
- Study coordinator: BRAGA, MARIA F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury